摘要
目的:探讨核苷(酸)类似物联合干扰素治疗慢性乙型肝炎的临床价值。方法:将在本院2008年2月～2011年8月收治的144例慢性乙肝患者随机分成两组:对照组72例,单纯采用重组人干扰素α-2b治疗;实验组72例,采用重组人干扰素α-2b+拉米夫定治疗。观察和比较两组的临床疗效、乙肝病毒脱氧核糖核酸(HBV DNA)转阴率、乙肝病毒e抗原(HBeAg)转阴率、HBeAg血清转换率和患者肝功能指标水平的变化情况。结果:实验组的总有效率明显高于对照组(P<0.05);实验组治疗后的HBV DNA转阴率、HBeAg转阴率、HBeAg血清转换率均显著高于对照组(P<0.05);实验组患者治疗后的丙氨酸转氨酶(ALT)、冬氨酸转氨酶(AST)、总胆红素(TBiL)水平显著低于对照组(P<0.05)。结论:临床应用核苷(酸)类似物联合干扰素治疗慢性乙型肝炎能提高乙肝标志物转阴率,改善患者的肝功能水平。
Objective. To investigate the clinical efficiency of lamivudine combining with recombi- nant human interferon α-2b in the treatment of chronic hepatitis B. Methods. A total of 144 patients of chronic hepatitis B that were admitted to our hospital from February 2008 to August 2011 were randomly divided into control group （n=72） and treatment group （n=72）. The control group was given recombi- nant human interferon α-2b only, and the treatment group was also given lamivudine. The clinical effica- cy, HBV-DNA negative rates, the HBeAg negative rates, the HBeAg seroconversion rates, and the level of liver function in 2 groups were observed and compared. Results： The total efficiency rate of the treat- ment group was significant higher than the control group（P〈0. 05） the HBV-DNA negative rates,HBeAg negative rates, and the HBeAg seroconversion rates of the treatment group were significantly higher than the control group（P〈0.05） the levels of ALT, AST, TBiL in the treatment group were sig- nificantly lower than the control group after treatment recombinant human interferon α-2b in the treatment rates of HBV markers and patient＇s liver function. （P〈0.05）. Conclusion： LamiVudine combining with of chronic hepatitis B can improve seroconversion
出处
《海南医学院学报》
CAS
2013年第2期209-211,共3页
Journal of Hainan Medical University
基金
中国高校医学期刊临床专项资金项目(112210522)~~
